PharmEasy
PrivateLast Round
Private Equity
Apr 29, 2024
Est. Valuation
$710M
Total Funding Raised
$3.35B
Company Overview
PharmEasy is a healthcare technology company that offers an online drug delivery platform to streamline the pharmaceutical supply chain and connect patients with local pharmacies and diagnostic centers for accessible and affordable healthcare services.
Sector
Healthcare & Life Sciences
Verticals
E-commerce, Telemedicine, Pharma Supply Chain, Medical AI
Business Model
B2C
Customer Profile
Marketplace Commission, Services & Consulting, Subscription SaaS
AI Layer
Application
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
PharmEasy Comparables
Compare PharmEasy with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Tata Consumer Products | 92% | |
| Tata Group | 83% | |
| Truemeds | 82% |
For institutional investors. Book with your work email.
PharmEasy Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Private Equity | Apr 29, 2024 | ||||
| Growth Equity | Feb 7, 2024 | ||||
| Corporate Funding | Oct 31, 2023 | ||||
| Debt | Aug 1, 2022 | ||||
| Debt | Apr 29, 2022 | ||||
Private Equity | Oct 18, 2021 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
PharmEasy Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Prosus | Private Equity, Corporate Funding, Growth Equity |
| Janus Henderson Group | Private Equity |
| EvolutionX Debt Capital | Private Equity, Growth Equity |
| DisruptAD | Corporate Funding, Private Equity |
| Temasek | Series F, Series E, Private Equity, Corporate Funding, Series D |
| Steadview Capital | Private Equity |
| Amansa Capital | Corporate Funding, Private Equity |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Feb 21, 2026
Samsung Health app now features integrated third-party healthcare services.
- Feb 21, 2026
Partnered with Samsung Health to integrate services into their app.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- partners_withSep 22, 2026
Pharmeasy partners with Fever on a three-week public awareness campaign in India from Aug 11th to Aug 31st '26 that encourages people to test for common monsoon-related illnesses instead of self-diagnosing symptoms as a routine viral fever.
- has_valuationAug 26, 2026
Pharmeasy, once valued at $5.6B, remains about 92% below its peak valuation, according to estimates by investor Janus Henderson.
For institutional investors. Book with your work email.
PharmEasy Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about PharmEasy's valuation, stock price, and market status.
Is PharmEasy a public or private company?
PharmEasy is a private company.
What is the current stock price of PharmEasy?
PharmEasy is a private company, so its shares have no public market price. Caplight tracks PharmEasy's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is PharmEasy worth (valuation)?
PharmEasy's valuation is estimated at $710.0M based on funding round data.
Can I buy PharmEasy stock?
PharmEasy shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was PharmEasy's last funding round?
PharmEasy's most recent funding round was Private Equity on April 29, 2024.
Who are the main investors in PharmEasy?
Key investors in PharmEasy include Temasek, Goldman Sachs (Asia) LLC, Orios Venture Partners, Eight Roads Ventures, TPG Growth.
Will PharmEasy IPO soon?
No public IPO plans have been announced for PharmEasy.
How can I track PharmEasy secondary market activity?
Caplight tracks bids, offers, and trades in PharmEasy's shares on secondary markets.